JUNYA FUJIMOTO

Last Updated :2025/06/04

Affiliations, Positions
Hiroshima University Hospital(Clinical Research Center in Hiroshima), Professor
E-mail
jfujimothiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Research Activities

Academic Papers

  1. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms., NPJ Precis Oncol., 8(1), 268, 20241119
  2. Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer., NPJ Precis Oncol., 8(1), 225, 20241005
  3. ★, Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment., Cancer Immunol Res., 12(12), 1736-1752, 20241203
  4. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis., Cancer Res., 84(13), 2060-2072, 20240702
  5. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes., Cancer Innov., 3(3), e112, 20240415
  6. CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning., Res Sq [Preprint], rs.3.rs-4359834, 20240520
  7. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion., Res Sq [Preprint], rs.3.rs-4396272, 20240515
  8. Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma., Int J Mol Sci., 25(4), 2331, 202402
  9. ★, An atlas of epithelial cell states and plasticity in lung adenocarcinoma., Nature., 627(8004), 656-663, 202403
  10. ★, Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study., J Thorac Oncol., 19(5), 719-731, 202405
  11. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer., JAMA Netw Open., 6(12), e2347700, 202312
  12. Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images., Mod Pathol., 37(2), 100398, 202312
  13. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma., J.Mod Pathol., 36(12), 100326, 202312
  14. Bronchial epithelial gene expression and interstitial lung abnormalities., Respir Res., 24(1), 245, 202310
  15. Unsupervised domain adaptation for nuclei segmentation: Adapting from hematoxylin & eosin stained slides to immunohistochemistry stained slides using a curriculum approach., Comput Methods Programs Biomed., 241(107768), 202311
  16. Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma., Cancer Commun. (Lond), 43(8), 951-955, 202308
  17. ★, Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial., Lancet., 402(10405), 871-881, 202309
  18. ★, Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial., Nat Med., 29(3), 593-604, 202307
  19. Glucocorticoid Mediated Inhibition of LKB1 Mutant Non-Small Cell Lung Cancers., Front Oncol., 13(1025443), 202303
  20. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer., J Clin Invest., 133(2), e160330, 20230117
  21. Analysis of immune intratumor heterogeneity highlights immunoregulatory and coinhibitory lymphocytes as hallmarks of recurrence in stage I NSCLC., Mod Pathol., 36(1), 100028, 202301
  22. ★, Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment., Lung Cancer., 172, 19-28, 202210
  23. ★, The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma., Cancer Discov., 12(11), 2626-2645, 202211
  24. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer., Br J Cancer., 123(7), 569-576, 202208
  25. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non–Small-Cell Lung Cancer Data Set., JCO Clin. Cancer Inform., 6(e2200040), 202207
  26. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung., Cancer Prev Res. (Phila), 15(7), 423-434, 202207
  27. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC., Clin Cancer Res., 28(11), 2461-2473, 202206
  28. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma., J Exp Clin Cancer Res., 41(1), 172, 202205
  29. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas., J Natl Cancer Inst., 114(2), 290-301, 202202
  30. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes., J Immunother Cancer., 10(2), e003082, 202202
  31. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics., Nat Commun., 12(1), 7081, 202112
  32. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer., Nat Commun., 12(1), 6655, 202111
  33. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers., Br J Cancer., 125(10), 1333-1340, 202111
  34. ★, Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing., Cancer Discov., 11(10), 2506-2523, 202110
  35. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study., Clin Cancer Res., 27(14), 3884-3895, 202107
  36. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features., Nat Commun., 12(1), 2722, 202105
  37. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients., Cancers. (Basel), 13(6), 1250, 202103
  38. ★, Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities., Cancer Cell., 39(3), 346-360, 202103
  39. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial., Nat Med., 27(3), 504-514, 202103
  40. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer., Commun Biol., 9(1), 314, 202103
  41. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer., J Thorac Oncol., 16(1), 127-139, 202101
  42. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas., Nat Commun., 12(1), 687, 202101
  43. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development., Am J Respir Crit Care Med., 203(1), 90-101, 202101
  44. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1., Pathol Res Pract., 216(12), 153267, 202012
  45. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity., Genome Biol., 21(1), 271, 202011
  46. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance Pathologist Evaluation of MET Protein Expression., Appl Immunohistochem Mol Morphol., 28(9), 669-677, 202010
  47. LKB1/STK11 expression in lung adenocarcinoma and associations with patterns of recurrence., Ann Thorac Surg., 110(4), 1131-1138, 202010
  48. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment., Clin Cancer Res., 26(20), 5477-5486, 202010
  49. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never-Smokers: Results From a Retrospective Multicenetr Cohort Study., Chest., 158(4), 1723-1733, 202010
  50. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix., Int J Gynecol Cancer., 30(9), 1303-1307, 202009
  51. Molecular differences across invasive lung adenocarcinoma morphological subgroups., Transl Lung Cancer Res., 9(4), 1029-1040, 202008
  52. (18)F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer., Cancer Immunol Immunother., 69(8), 1519-1534, 202008
  53. Comparative genomics of high grade neuroendocrine carcinoma of the cervix., PLoS One., 15(6), e0234505, 202006
  54. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype., J Thorac Oncol., 15(5), 777-791, 202005
  55. Genomic Assessment Distinguishes Intrapulmonary Metastases From Synchronous Primary Lung Cancers., J Thorac Dis., 12(5), 1952-1959, 202005
  56. Computational staining of pathology images to study tumor microenvironment in lung cancer., Cancer Res., 80(10), 2056-2066, 202005
  57. Immune Regulatory Markers of Lepidic-Pattern Adenocarcinomas Presenting as Ground Glass Opacities., J Thorac Dis., 12(3), 329-337, 202003
  58. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small cell lung cancer., Nat Cancer., 1, 423-426, 202002
  59. Comprehensive T cell repertoire characterization of non-small cell lung cancer., Nat Comm., 11(1), 603, 202001
  60. ConvPath: A Software Tool for Lung Adenocarcinoma Digital Pathological Image Analysis Aided by a Convolutional Neural Network., EBiomedicine, 50, 103-110, 201912
  61. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice., Cancer., 125(21), 3738-3748, 201911
  62. Artificial Intelligence in Lung Cancer Pathology Image Analysis., Cancers. (Basel), 11(11), 201910
  63. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer., J Thorac Cardiovasc Surg., 158(3), 911-919, 201909
  64. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer., Ann Oncol., 30(9), 1521-1530, 201909
  65. ★, Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer., Am J Respir Crit Care Med., 200(6), 742-750, 201909
  66. ★, Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma., Nat Commun., 10(1), 2978, 201907
  67. An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer., Transl Oncol., 12(6), 836-845, 201906
  68. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer., Cancer Discov., 9(5), 646-661, 201905
  69. Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study., Sci Rep., 9(1), 6886, 201905
  70. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung., EBioMedicine., 42, 296-303, 201904
  71. Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived from Murine Lung Adenocarcinoma with Somatic Kras Mutations., Front Oncol., 9(207), 201904
  72. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases., Appl Immunohistochem Mol Morphol., 27(2), 125-133, 201902
  73. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer., Oncotarget., 9(102), 37662-37675, 201812
  74. Integrative Molecular Characterization of Malignant Pleural Mesothelioma., Cancer Discov., 8(12), 1548-1565, 201812
  75. Transcriptomic alterations in lung adenocarcinoma unveil new mechanisms targeted by the TBX2 subfamily of tumor suppressor genes., Front Oncol., 8(482), 201810
  76. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer., Cell Rep., 25(5), 1304-1317, 201810
  77. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-beta Superfamily., Cell Syst., 7(4), 422-437, 201810
  78. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes., Int J Mol Sci., 23(18), 10930, 201809
  79. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients., Cancer Cell., 34(2), 211-224, 201808
  80. Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome., Sci Rep., 8(1), 10393, 201807
  81. Multiregion gene-expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer., Mod Pathol., 31(6), 947-955, 201806
  82. A randomized, double blinded, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed sensitive or refractory small cell lung cancer., J Clin Oncol., 36(23), 2386-2394, 201806
  83. The Immune Landscape of Cancer., Immunity., 48(4), 812-830, 201804
  84. The epithelial-to-mesenchymal transition activator ZEB1 initiates a pro-metastatic competing endogenous RNA network., J Clin Invest., 128(4), 1267-1282, 201804
  85. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Cell Rep., 23(1), 313-326, 201804
  86. Systematic Analysis of Splice-Site-Creating Mutations in Cancer., Cell Rep., 23(1), 270-281, 201804
  87. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images., Cell Rep., 23(1), 181-193, 201804
  88. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types., Cell Rep., 23(1), 282-296, 201804
  89. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics., Cell., 173(2), 305-320, 201804
  90. Pathogenic Germline Variants in 10,389 Adult Cancers., Cell., 173(2), 355-370, 201804
  91. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context., Cell Rep., 23(1), 297-312, 201804
  92. Oncogenic Signaling Pathways in The Cancer Genome Atlas., Cell., 173(2), 321-337, 201804
  93. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers., Cell Rep., 23(1), 255-269, 201804
  94. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation., Cell., 173(2), 338-354, 201804
  95. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas., Cell Rep., 23(1), 172-180, 201804
  96. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer., Cancer Cell., 33(4), 706-720, 201804
  97. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types., Cell Rep., 23(1), 213-226, 201804
  98. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas., Cell Rep., 23(1), 194-212, 201804
  99. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas., Cell Rep., 23(1), 239-254, 201804
  100. Genomic and Functional Approaches to Understanding Cancer Aneuploidy., Cancer Cell., 33(4), 690-705, 201804
  101. Genome-wide expression changes in the normal-appearing airway during the evolution of smoking-associated lung adenocarcinoma., Cancer Prev Res, (Phila), 11(4), 237-248, 201804
  102. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers., Cell Rep., 23(1), 227-238, 201804
  103. Comprehensive Characterization of Cancer Driver Genes and Mutations., Cell., 173(2), 371-385, 201804
  104. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas., Cancer Cell., 33(4), 721-735, 201804
  105. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer., Cell., 173(2), 291-304, 201804
  106. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics., Cell., 173(2), 400-416, 201804
  107. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples., Cell., 173(2), 386-399, 201804
  108. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers., Cancer Cell., 33(4), 690-705, 201804
  109. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2)., Clin Cancer Res., 24(5), 1038-1047, 201803
  110. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer., Lung Cancer., 117, 73-79, 201803
  111. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines., Cell Syst., 6(3), 271-281, 201803
  112. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas., Cell Syst., 6(3), 282-300, 201803
  113. The integrated genomic landscape of thymic epithelial tumors., Cancer Cell., 33(2), 244-258, 201802
  114. Biomarker-Integrated Phase I Trial of Neoadjuvant Dasatinib in Resectable Malignant Pleural Mesothelioma., J Thorac Oncol., 13(2), 246-257, 201802
  115. RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer., Clin Cancer Res., 24(2), 341-350, 201801
  116. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma., Cancer Res., 77(22), 6119-6130, 201711
  117. Quantitative proteomic analysis of optimal cutting temperature (OCT) embedded core needle biopsy of lung cancer, J Am Soc Mass Spectrom., 28(10), 2078-2089, 201710
  118. ★, Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a., Int J Cancer., 141(8), 1589-1599, 201710
  119. Protein expression of TTF1 and cMyc define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies., Oncotarget., 8(43), 73419-73432, 201709
  120. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma., Oncotarget., 8(56), 95466-95480, 201709
  121. TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection., Oncotarget., 8(40), 68230-68241, 201708
  122. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer., JAMA Oncol., 3(8), 1051-1058, 201708
  123. A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with Platinum Etoposide Chemotherapy in Platinum Refractory Small Cell Lung Cancer Patients., Oncotarget., 8(46), 81441-81454, 201708
  124. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence., Cancer Discov., 7(10), 1088-1097, 201710
  125. Dynamic Variations in Epithelial-to-Mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP inhibitors and Cisplatin in Small Cell Lung Cancer., Oncotarget., 8(27), 28575-28587, 201704
  126. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up., Ann Oncol., 28(1), 75-82, 201703
  127. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms., Mod Pathol., 30(6), 826-833, 201706
  128. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas., Oncotarget., 8(13), 21994-22002, 201703
  129. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases., Hum Pathol., 59(1-9), 201701
  130. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function., Ann Oncol., 28(1), 83-89, 201701
  131. Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer., Retrovirology., 14(1), 3, 201701
  132. Genomic heterogeneity of multiple synchronous lung cancer., Nat Commun., 21(7), 13200, 201610
  133. The genomic landscape of allelic imbalance in the normal-appearing airway field of cancerization., Cancer Res., 76(13), 3676-3683, 201607
  134. Validation of SCT Methylation As a Hallmark Biomarker for Lung Cancers., J Thorac Oncol., 11(3), 346-360, 201512
  135. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells., Sci Rep., 7(5), 13846, 201509
  136. Multi-institutional driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience., J Thorac Oncol., 10(5), 768-777, 201505
  137. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers., Hum Pathol., 46(3), 376-383, 201503
  138. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases., Hum Pathol., 45(12), 2463-2470, 201412
  139. ★, Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing., Science., 346(6206), 256-259, 201412
  140. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers., Proc Natl Acad Sci U S A., 111(41), 14788-14793, 201410
  141. Copper Transporter CTR1 Expression and Tissue Platinum Concentration in Non-Small Cell Lung Cancer., Lung Cancer., 85(1), 88-93, 201407
  142. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma., Ann Diagn Pathol., 18(3), 140-145, 201406
  143. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma., Clin Lung Cancer., 15(3), 197-201, 201405
  144. Transcriptomic architecture of the adjacent airway field cancerization in nonsmall cell lung cancer., J Natl Cancer Inst., 106(3), dju004, 201403
  145. Laser Capture Microdissection for the Investigative Pathologist., Vet Pathol., 51(1), 2463-2470, 201401
  146. Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma., Clin Cancer Res., 19(22), 6261-6271, 201311
  147. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer., Clin Cancer Res., 19(13), 3383-3395, 201305
  148. Comparable molecular alterations in 4-nitroquinoline 1-ooxide induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients., In Vivo., 27(4), 473-484, 201307
  149. Characterizing the molecular spatial and temporal field of injury in early stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling., Cancer Prev Res. (Phila), 6(1), 8-17, 201301
  150. ★, G-protein coupled receptor family C group 5 member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small cell lung cancer., J Thorac Oncol., 7(12), 1747-1754, 201212
  151. Tissue Platinum Concentration and Tumor Response in Non-small Cell Lung Cancer., J Clin Oncol., 30(27), 3345-3352, 201208
  152. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1., Cancer Discov., 2(9), 798-811, 201209
  153. HER family receptor and ligand status in thymic carcinoma., Lung Cancer., 77(3), 515-521, 201206
  154. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma., J Thorac Oncol., 6(12), 2104-2111, 201112
  155. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis., Clin Cancer Res., 17(8), 2434-2443, 201104
  156. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung., PLoS One., 5(2), e9112, 2010
  157. ★, Comparative Functional Genomics Analysis of NNK Tobacco-Carcinogen Induced Lung Adenocarcinoma Development in Gprc5a-Knockout Mice., PLoS One., 5(7), e11847, 2010
  158. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine Lif., Cancer Res., 70(21), 8917-8926, 201010
  159. Validation of a Novel Statistical Model for Assessing the Synergy of Combined-agent Cancer Chemoprevention., Cancer Prev Res. (Phila), 3(8), 917-928, 201007
  160. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent and associated with survival in human lung adenocarcinomas, Neoplasia, 12(6), 499-505, 201006
  161. Knockout of the Tumor Suppressor Gene Gprc5a in Mice Leads to NF-{kappa}B Activation in Airway Epithelium and Promotes Lung Inflammation and Tumorigenesis., Cancer Prev Res. (Phila), 3(4), 424-437, 201004
  162. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene., J Natl Cancer Inst., 99(22), 1668-1682, 200711
  163. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol Rep., 11(1), 9-15, 200401
  164. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach., J Gastroenterol., 35(Suppl(12)), 111-115, 2000
  165. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis., Cancer Lett., 149(1-2), 125-134, 200002
  166. Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype., Int J Cancer., 83(2), 192-196, 199910
  167. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma., Oncol Rep., 6(5), 983-987, 199909
  168. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas., Pathobiology, 67(4), 174-179, 199907
  169. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach, Jpn J Cancer Res., 90(6), 589-595, 199906
  170. Microsatellite instabilities in gastric cancer patients with multiple primary cancers., Int J Oncol., 14(1), 151-155, 199901
  171. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas., Jpn J Cancer Res., 89(11), 1099-1103, 199811
  172. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression., Int J Oncol., 12(6), 1253-1258, 199806
  173. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections., Oncogene, 18(8), 1561-1567, 199902